UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1428, 2026

Bionano Genomics, Inc.

(Exact Name of Registrant as Specified in its Charter)

     Delaware

     001-38613

     26-1756290

     (State or Other Jurisdiction
of Incorporation)

     (Commission
File Number)

     (IRS Employer
Identification No.)

     9540 Towne Centre Drive, Suite 100
San Diego, California

     92121

     (Address of Principal Executive Offices)

     (Zip Code)

Registrant’s telephone number, including area code: (858) 888-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	BNGO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 58.0701 ~~Submission~~Other ~~of Matters to a Vote of Security Holders~~Events.

On May 1428, 2026, Bionano Genomics, Inc. (the “Company”) ~~held~~announced ~~its~~that ~~2026~~it ~~Annual~~repaid ~~Meeting~~in offull ~~Stockholders~~all outstanding Senior Secured Convertible Debentures (the “~~Annual Meeting~~Debentures”). Ason ofMay ~~March 19~~26, 2026, the ~~record~~scheduled maturity date. ~~for~~Any ~~the~~liens ~~Annual~~on ~~Meeting (~~the ~~“Record~~Company’s ~~Date”)~~assets, ~~11,091,615~~and ~~shares~~any covenants under the terms of the ~~Company’s~~agreements ~~common~~governing ~~stock~~the Debentures, were ~~outstanding~~also ~~and~~terminated ~~entitled~~in toaccordance ~~vote~~with attheir terms. On May 28, 2026, the ~~Annual~~Company ~~Meeting.~~issued Aa ~~summary~~press release related to the extinguishment of the ~~matters~~Debentures, ~~voted~~a ~~upon~~copy byof ~~stockholders~~which atis ~~the~~attached ~~Annual~~as ~~Meeting~~Exhibit 99.1 to this Current Report on Form 8-K and is ~~set~~hereby ~~forth~~incorporated ~~below~~by reference herein.

AItem ~~total of 4,225,995 shares of the Company’s common stock were present at the Annual Meeting in person, by virtual attendance, or by proxy, which represents approximately 38~~9.1%01 ofFinancial ~~the~~Statements ~~shares of the Company’s common stock outstanding~~ and ~~entitled to vote at the Annual Meeting as of the Record Date~~Exhibits.

~~Proposal~~(d) ~~1. Election of Directors.~~Exhibits

The Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows:


Exhibit No.		Description
99.1		Press release issued May 28, 2026, announcing full retirement of outstanding senior secured convertible debentures.
104		Inline XBRL for the cover page of this Current Report on Form 8-K

Name	Votes For	Votes Withheld	Broker Non-Votes
Albert Luderer, Ph.D.	847,601	143,790	3,234,604
Kristiina Vuori, M.D., Ph.D.	867,474	123,917	3,234,604

Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers.

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The final voting results were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
697,999		216,553		76,839		3,234,604

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm.

The Company’s stockholders ratified the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
3,770,715		206,541		248,739		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Bionano Genomics, Inc.
Date: May 14, 2026	By:	/s/ Albert A. Luderer, Ph.D.
Date: May 28, 2026	By:	/s/ Albert A. Luderer, Ph.D.
		Albert A. Luderer, Ph.D.
		Interim Chief Executive Officer

Filing Compare · Bionano Genomics, Inc.